Osiris Therapeutics Inc. (OSIR) Financials Nov 14, 2014, 4:28 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Osiris Therapeutics Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 44.53M 43.2M 42.4M 11.8M 24.31M
Cost of Goods Sold (COGS) incl. D&A - 817,000 1.28M 2.55M 6.66M
COGS excluding D&A - 62,000 531,000 1.84M 6.07M
Depreciation & Amortization Expense 875,000 755,000 745,000 708,000 587,000
Depreciation - - 745,000 - 587,000
Amortization of Intangibles - - 0 - 0
Gross Income - 42.39M 41.13M 9.25M 17.65M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 70.7M 29.04M 24.37M 20.4M 20.49M
Research & Development 63.27M 23.5M 19.16M 14.11M 4.95M
Other SG&A 7.44M 5.53M 5.22M 6.3M 15.53M
Other Operating Expense 495,000 161,000 1.92M 0 0
Unusual Expense 0 0 0 0 (401,000)
EBIT after Unusual Expense 0 0 0 0 401,000
Non Operating Income/Expense 0 175,000 100,000 49,000 13,000
Non-Operating Interest Income 1.29M 0 - 0 0
Equity in Affiliates (Pretax) 0 0 0 - 0
Interest Expense 8,000 0 0 - -
Gross Interest Expense 8,000 0 0 - -
Interest Capitalized 0 0 0 - -
Pretax Income (26.26M) 13.37M 14.94M (11.1M) (2.42M)
Income Tax (2.7M) 241,000 43,000 (37,000) (1.33M)
Income Tax - Current Domestic (2.7M) - - - -
Income Tax - Current Foreign 0 0 - - -
Income Tax - Deferred Domestic 0 0 - - -
Income Tax - Deferred Foreign 0 0 - - -
Income Tax Credits 0 0 - - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (23.56M) 13.13M 14.89M (11.07M) (1.09M)
Minority Interest Expense 0 0 0 0 0
Net Income (23.56M) 13.13M 14.89M (11.07M) (1.09M)
Extraordinaries & Discontinued Operations 38.14M 0 0 0 42.73M
Extra Items & Gain/Loss Sale Of Assets 37.05M 0 0 0 49.4M
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 1.08M 0 0 0 (6.67M)
Net Income After Extraordinaries 14.57M 13.13M 14.89M (11.07M) 41.64M
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (23.56M) 13.13M 14.89M (11.07M) (1.09M)
EPS (Basic) (0.69) 0.40 0.45 (0.34) (0.23)
Basic Shares Outstanding 32.74M 32.78M 32.82M 32.86M 33.31M
EPS (Diluted) (0.69) 0.40 0.45 (0.34) (0.23)
Diluted Shares Outstanding 32.74M 33.1M 33.12M 32.86M 33.31M
EBITDA (26.67M) 13.95M 15.58M (10.44M) (2.25M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Osiris Therapeutics Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 44.53M 43.2M 42.4M 11.8M 24.31M
Cost of Goods Sold (COGS) incl. D&A - 817,000 1.28M 2.55M 6.66M
COGS excluding D&A - 62,000 531,000 1.84M 6.07M
Depreciation & Amortization Expense 875,000 755,000 745,000 708,000 587,000
Depreciation - - 745,000 - 587,000
Amortization of Intangibles - - 0 - 0
Gross Income - 42.39M 41.13M 9.25M 17.65M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 70.7M 29.04M 24.37M 20.4M 20.49M
Research & Development 63.27M 23.5M 19.16M 14.11M 4.95M
Other SG&A 7.44M 5.53M 5.22M 6.3M 15.53M
Other Operating Expense 495,000 161,000 1.92M 0 0
Unusual Expense 0 0 0 0 (401,000)
EBIT after Unusual Expense 0 0 0 0 401,000
Non Operating Income/Expense 0 175,000 100,000 49,000 13,000
Non-Operating Interest Income 1.29M 0 - 0 0
Equity in Affiliates (Pretax) 0 0 0 - 0
Interest Expense 8,000 0 0 - -
Gross Interest Expense 8,000 0 0 - -
Interest Capitalized 0 0 0 - -
Pretax Income (26.26M) 13.37M 14.94M (11.1M) (2.42M)
Income Tax (2.7M) 241,000 43,000 (37,000) (1.33M)
Income Tax - Current Domestic (2.7M) - - - -
Income Tax - Current Foreign 0 0 - - -
Income Tax - Deferred Domestic 0 0 - - -
Income Tax - Deferred Foreign 0 0 - - -
Income Tax Credits 0 0 - - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (23.56M) 13.13M 14.89M (11.07M) (1.09M)
Minority Interest Expense 0 0 0 0 0
Net Income (23.56M) 13.13M 14.89M (11.07M) (1.09M)
Extraordinaries & Discontinued Operations 38.14M 0 0 0 42.73M
Extra Items & Gain/Loss Sale Of Assets 37.05M 0 0 0 49.4M
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 1.08M 0 0 0 (6.67M)
Net Income After Extraordinaries 14.57M 13.13M 14.89M (11.07M) 41.64M
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (23.56M) 13.13M 14.89M (11.07M) (1.09M)
EPS (Basic) (0.69) 0.40 0.45 (0.34) (0.23)
Basic Shares Outstanding 32.74M 32.78M 32.82M 32.86M 33.31M
EPS (Diluted) (0.69) 0.40 0.45 (0.34) (0.23)
Diluted Shares Outstanding 32.74M 33.1M 33.12M 32.86M 33.31M
EBITDA (26.67M) 13.95M 15.58M (10.44M) (2.25M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
